- Home
- BFST vs IVA Comparison
BFST vs IVA Comparison
Compare BFST & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- IVA
- Stock Information
- Founded
- BFST 2006
- IVA 2011
- Country
- BFST United States
- IVA France
- Employees
- BFST N/A
- IVA N/A
- Industry
- BFST Major Banks
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- BFST Finance
- IVA Health Care
- Exchange
- BFST Nasdaq
- IVA Nasdaq
- Market Cap
- BFST 719.4M
- IVA 769.0M
- IPO Year
- BFST 2018
- IVA 2020
- Fundamental
- Price
- BFST $23.92
- IVA $5.72
- Analyst Decision
- BFST Strong Buy
- IVA Strong Buy
- Analyst Count
- BFST 3
- IVA 7
- Target Price
- BFST $30.00
- IVA $16.00
- AVG Volume (30 Days)
- BFST 93.3K
- IVA 61.2K
- Earning Date
- BFST 10-23-2025
- IVA 09-29-2025
- Dividend Yield
- BFST 2.38%
- IVA N/A
- EPS Growth
- BFST 3.92
- IVA N/A
- EPS
- BFST 2.51
- IVA N/A
- Revenue
- BFST $291,096,000.00
- IVA $19,929,536.00
- Revenue This Year
- BFST $25.00
- IVA N/A
- Revenue Next Year
- BFST $17.32
- IVA N/A
- P/E Ratio
- BFST $9.37
- IVA N/A
- Revenue Growth
- BFST 17.48
- IVA N/A
- 52 Week Low
- BFST $20.07
- IVA $1.60
- 52 Week High
- BFST $30.30
- IVA $6.55
- Technical
- Relative Strength Index (RSI)
- BFST 46.93
- IVA 49.05
- Support Level
- BFST $23.05
- IVA $5.59
- Resistance Level
- BFST $24.32
- IVA $6.55
- Average True Range (ATR)
- BFST 0.46
- IVA 0.35
- MACD
- BFST -0.03
- IVA -0.04
- Stochastic Oscillator
- BFST 50.78
- IVA 18.75
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.